Degrading the anaplastic lymphoma kinase protein to treat paediatric cancers
Dr Lizzie Tucker will assess a new type of treatment to fight ALK-driven childhood cancers like neuroblastoma.
Understanding new treatment options for when treatment for neuroblastoma doesn’t work or the cancer grows back
Dr Jess Morgan at the University of York will review the latest experimental treatments for hard-to-treat neuroblastoma to help with decision-making.
Understanding how neuroblastoma and immune cells join forces
Studying how neuroblastoma cells and immune cells interact over time to see how the cancer adapts to treatment.
What happens in cells to make neuroblastoma develop and how can we stop this?
Looking at what extra pieces of chromosomes do in neuroblastoma and how these work with the MYCN protein to convert healthy cells into cancer cells.
Developing a kinder and more effective immunotherapy for neuroblastoma
Modifying current immunotherapy so that it doesn't cause damage to nerve cells and instead targets three molecules to help kill neuroblastoma cells more effectively.
Understanding what the red flags are in aggressive neuroblastoma to improve and develop treatments
Finding out which changes to how DNA is read in neuroblastoma can give doctors more information about the cancer, and investigating whether these changes could be stopped through medicines.
Understanding chemotherapy doesn’t work as well for some children with neuroblastoma
Investigating how cancer cells can keep dividing and why this makes it harder to treat.
Using anti-depressants to improve immunotherapy for neuroblastoma
Using anti-depressants to prevent the body's immune system from fighting immunotherapy treatments.
Testing existing drugs in new combinations for high-risk neuroblastoma
Testing whether a combination of drugs could reduce the risk of relapse and limit side effects.